BioStem Technologies, Inc. (OTCMKTS:BSEM) Short Interest Up 174.3% in July

Key Points

• Short interest in BioStem Technologies, Inc. increased dramatically by 174.3% in July, reaching a total of 214,800 shares by July 31.
• The company has a market capitalization of $117.92 million and its shares opened at $7.04 on Friday, with a 12-month trading range between $5.02 and $28.26.
• BioStem Technologies focuses on developing pharmaceutical and regenerative medicine products aimed at treating various medical conditions, including joint pain and autoimmune diseases.

BioStem Technologies, Inc. (OTCMKTS:BSEM - Get Free Report) saw a significant increase in short interest in July. As of July 31st, there was short interest totaling 214,800 shares, anincreaseof174.3% from the July 15th total of 78,300 shares. Approximately1.3% of the company's stock are sold short. Based on an average trading volume of 76,900 shares, the short-interest ratio is currently 2.8 days. Based on an average trading volume of 76,900 shares, the short-interest ratio is currently 2.8 days. Approximately1.3% of the company's stock are sold short.

BioStem Technologies Price Performance

Shares of OTCMKTS:BSEM traded down $0.16 during midday trading on Thursday, hitting $5.99. 63,290 shares of the company's stock were exchanged, compared to its average volume of 64,098. The stock has a 50 day moving average price of $11.50 and a 200-day moving average price of $12.10. The company has a market cap of $100.31 million, a PE ratio of 5.25 and a beta of -0.29. BioStem Technologies has a 12 month low of $5.02 and a 12 month high of $28.2565.

BioStem Technologies Company Profile

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases.